Effects of sustained phencyclidine exposure on sensorimotor gating of startle in rats

Neuropsychopharmacology

Volumn 21, Issue 1, 1999, Pages 28-39

  Martinez, Zoë A ^a   Ellison, Gaylord D ^a   Geyer, Mark A ^b   Swerdlow, Neal R ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Apomorphine; Phencyclidine; Prepulse inhibition; Schizophrenia; Sensorimotor; Startle

Indexed keywords

APOMORPHINE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; PHENCYCLIDINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; FEMALE; HABITUATION; INTRAPERITONEAL DRUG ADMINISTRATION; NONHUMAN; OSMOTIC MINIPUMP; PREPULSE INHIBITION; PRIORITY JOURNAL; RAT; SCHIZOPHRENIA; STARTLE REFLEX; SUBCUTANEOUS DRUG ADMINISTRATION;

ANIMALS; APOMORPHINE; DOPAMINE AGONISTS; DRUG IMPLANTS; EXCITATORY AMINO ACID ANTAGONISTS; FEMALE; HABITUATION, PSYCHOPHYSIOLOGIC; HALLUCINOGENS; INJECTIONS, INTRAPERITONEAL; INJECTIONS, SUBCUTANEOUS; MALE; PHENCYCLIDINE; RATS; RATS, SPRAGUE-DAWLEY; STARTLE REACTION; TIME FACTORS;

EID: 0033015347     PISSN: 0893133X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0893-133X(98)00137-7     Document Type: Article

References (51)

1. Andreasen N.C. Linking mind and brain in the study of mental illnesses. A project for scientific psychopathology Science. 275:1997;1586-1593.
2. Allen R.M., Young S.J. Phencyclidine-induced psychosis. Am J Psychiatry. 135:1978;1081-1084.
3. Bakshi V.P., Swerdlow N.R., Geyer M.A. Clozapine antagonizes phencyclidine-induced deficits in sensorimotor gating of the startle response. J Pharmacol Exp Ther. 271:1994;787-794.
4. Bakshi V.P., Geyer M.A. Multiple limbic regions mediate the disruption of prepulse inhibition produced in rats by the noncompetitive NMDA antagonist dizocilpine. J Neurosci. 18:1998;8394-8401.
5. Bolino F., Di Michele V., Di Cicco L., Manna V., Danelluzzo E., Casacchia M. Sensorimotor gating and habituation evoked by electrocutaneous stimulation in schizophrenia. Biol Psychiatry. 36:1994;670-679.
6. Braff D., Grillon C., Geyer M. Gating and habituation of the startle reflex in schizophrenic patients. Arch Gen Psychiatry. 49:1992;206-215.
7. Braff D., Stone C., Callaway E., Geyer M.A., Glick I.D., Bali L. Prestimulus effects on human startle reflex in normals and schizophrenics. Psychophysiology. 15:1978;339-343.
8. Braff D.L., Swerdlow N.R., Geyer M.A. Prepulse intensity of the startle response in schizophrenia. The effects of varying prepulse intensity and gender:1995;p 107, Proc Amer Coll Neuropsychopharmacology.
9. Breier A., Malhotra A.K., Pinals D.A., Weisenfeld N.I., Pickar D. Association of ketamine-induced psychosis with focal activation of the prefrontal cortex in healthy volunteers. Am J Psychiatry. 154:1997;805-811.
10. Burns R.S., Lerner S.E. Perspectives. Acute phencyclidine intoxication Clin Toxicol. 9:1976;477-501.
11. Domino E.F. Neurobiology of phencyclidine (Sernyl), a drug with an unusual spectrum of pharmacological activity. Int Rev Neurobiol. 6:1964;303-347.
12. Ellison G. Neuronal degeneration following both competitive and non-competitive NMDA antagonists. NeuroReport. 5:1994;2688-2692.
13. Ellison G., Switzer R.C. Dissimilar patterns of degeneration in brain following four different addictive stimulants. NeuroReport. 5:1993;17-20.
14. Ellison G.D., Keys A.S. Persisting changes in brain glucose uptake following neurotoxic doses of phencyclidine which mirror the acute effects of the drug. Psychopharmacology. 126:1996;271-274.
15. Fauman M., Fauman B. Chronic phencyclidine (PCP) abuse. A psychiatric perspective J Psychedelic Drugs. 12:1980;307-315.
16. Frith C. Neuropsychology of schizophrenia, what are the implications of intellectual and experiential abnormalities for the neurobiology of schizophrenia? Br Med Bull. 52:1996;618-626.
17. Geyer M.A., Braff D.L. Habituation of the blink reflex in normals and schizophrenic patients. Psychophysiology. 19:1982;1-6.
18. Geyer MA, Swerdlow NR (1998): Measurement of startle response, prepulse inhibition, and habituation. In JN Crawley & P Skolnick (Eds.), Current Protocols in Neuroscience, New York, John Wiley & Sons, pp 8.7.1-8.7.15.
19. Graeven D., Sharp J. Acute effects of phencyclidine (PCP) on chronic and recreational users. Am J Drug and Alcohol Abuse. 8:1981;39-50.
20. Grillon C., Ameli R., Charney D.S., Krystal J., Braff D. Startle gating deficits occur across prepulse intensities in schizophrenic patients. Biol Psychiatry. 32:1992;939-943.
21. Hoffman D.C., Donovan H., Cassella J.V. The effects of haloperidol and clozapine on the disruption of sensorimotor gating induced by the noncompetitive glutamate antagonist MK-801. Psychopharmacology. 111:1993;339-344.
22. Javitt D. Negative schizophrenic symptomatology and the PCP (phencyclidine) model of schizophrenia. Hillside J Clin Psychiatry. 9:1987;12-35.
23. Javitt D.C., Zukin S.R. Recent advances in the phencyclidine model of schizophrenia. Am J Psychiatry. 148:1991;1301-1308.
24. Jentsch J.D., Tran A., Le D., Youngren K.D., Roth R.H. Subchronic phencyclidine administration reduces mesoprefrontal dopamine utilization and impairs prefrontal cortical-dependent cognition in the rat. Neuropsychopharmacology. 17:1997;92-99.
25. Jentsch J.D., Taylor J.R., Roth R.H. Subchronic phencyclidine administration increases mesolimbic dopaminergic system responsivity and augments stress- and psychostimulant-induced hyperlocomotion. Neuropsychopharmacol. 19:1998;105-113.
26. Keith V.A., Mansbach R.S., Geyer M.A. Failure of haloperidol to block the effects of phencyclidine and dizocilpine on prepulse inhibition of startle. Biol Psychiatry. 30:1991;557-566.
27. Krystal J.H., Karper L.P., Seibyl J.P., Freeman G.K., Delaney R., Bremner J.D., Heninger G.R., Bowers M.B. Jr., Charney D.S. Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Arch Gen Psychiatry. 51:1994;199-214.
28. Lahti A.C., Holcomb H.H., Medoff D.R., Tamminga C.A. Ketamine activates psychosis and alters limbic blood flow in schizophrenia. NeuroReport. 6:1995;869-872. a.
29. Lahti A.C., Koffel B., LaPorte D., Tamminga C.A. Subanesthetic doses of ketamine stimulate psychosis in schizophrenia. Neuropsychopharmacol. 13:1995;9-19. b.
30. Lipton J., Zeigler S., Wilkins J., Ellison G. A silicone pellet for continuous cocaine. Comparison with continuous amphetamine Pharmacol Biochem Behav. 38:1991;927-930.
31. Malhotra A.K., Pinals D.A., Weingartner H., Sirocco K., Missar C.D., Pickar D., Breier A. NMDA receptor function and human cognition. The effects of ketamine in healthy volunteers Neuropsychopharmacology. 14:1996;301-307.
32. Malhotra A.K., Adler C.A., Kennison S.D., Elman I., Pickar D., Breier A. Clozapine blunts N-methyl-D-aspartatate antagonist induced psychosis. A study with ketamine Biol Psychiatry. 42:1997;664-668.
33. Mansbach R.S., Geyer M.A. Effects of phencyclidine and phencyclidine biologs on sensorimotor gating in the rat. Neuropsychopharmacol. 2:1989;299-308.
34. Mansbach R.S., Geyer M.A. Parametric determinants in pre-stimulus modification of acoustic startle. Interaction with ketamine Psychopharmacology. 105:1991;162-168.
35. Mansbach R.S., Geyer M.A., Braff D.L. Dopaminergic stimulation disrupts sensorimotor gating in the rat. Psychopharmacology. 94:1988;507-514.
36. McCarron M.M., Schulze B.W., Thompson G.A., Concer M.C., Goetz W.A. Acute phencyclidine intoxication. Clinical patterns, complications, and treatment Annals Emergency Medicine. 10:1981;290-297.
37. Pearlson G. Psychiatric and medical syndromes with phencyclidine (PCP) abuse. Johns Hopkins Med J. 148:1981;25-33.
38. Perry W., Braff D. Information-processing deficits and thought disorder in schizophrenia. Am J Psychiatry. 151:1994;363-367.
39. Rainey J.M., Crowder M.K. Prolonged psychosis attributed to phencyclidine. Report of three cases Am J Psychiatry. 132:1975;1076-1078.
40. Reijmers L.G., Vanderheyden P.M., Peeters B.W. Changes in prepulse inhibition after local administration of NMDA receptor ligands in the core regions of the rat nucleus accumbens. Eur J Pharmacol. 272:1995;131-138.
41. Sams-Dodd F. A test of predictive validity of animal models of schizophrenia based on phencyclidine and D-amphetamine. Neuropsychopharmacology. 18:1998;293-304.
42. Snell L., Yi S., Johnson K. Comparison of the effects of MK-801 and phencyclidine on catecholamine uptake and NMDA-induced norepinephrine release. Eur J Pharmacol. 145:1988;223-226.
43. Swerdlow N.R., Braff D.L., Geyer M.A., Koob G.F. Central dopamine hyperactivity in rats mimics abnormal acoustic startle response in schizophrenics. Biol Psychiatry. 21:1986;23-33.
44. Swerdlow N.R., Braff D.L., Masten V.L., Geyer M.A. Schizophrenia-like sensorimotor gating abnormalities in rats following dopamine infusion into the nucleus accumbens. Psychopharmacology. 101:1990;414-420. a.
45. Swerdlow N.R., Braff D.L., Taaid N., Geyer M.A. Assessing the validity of an animal model of deficient sensorimotor gating in schizophrenic patients. Arch Gen Psychiatry. 51:1994;139-154.
46. Swerdlow N.R., Geyer M.A. Clozapine and haloperidol in an animal model of sensorimotor gating deficits in schizophrenia. Pharmacol Biochem Behav. 44:1993;741-744.
47. Swerdlow N.R., Geyer M.A. Using an animal model of deficient sensorimotor gating to study the pathophysiology and new treatments of schizophrenia. Schizophrenia Bull. 24:1998;285-302.
48. Swerdlow N.R., Mansbach R.S., Geyer M.A., Pulvirenti L., Koob G.F., Braff D.L. Amphetamine disruption of prepulse inhibition of acoustic startle is reversed by depletion of mesolimbic dopamine. Psychopharmacology. 100:1990;413-416. b.
49. Tamminga C.A., Thaker G.K., Buchanan R., Kirkpatrick B., Alphs L.D., Chase T.N., Carpenter W.T. PCP-induced alterations in cerebral glucose utilization in the rat brain. Blockade by metaphit, a PCP-receptor-acylating agent Synapse. 1:1987;497-504.
50. Wan F.J., Swerdlow N.R. The basolateral amygdala regulates sensorimotor gating of acoustic startle in the rat. Neuroscience. 76:1997;715-724.
51. Weissman A., Marquis K., Moreton J., London E. Effects of self-administered phencyclidine on regional uptake of 2-deoxy-D-[1-14C]glucose in brain. Neuropharmacology. 28:1989;575-583.